Vatalanib succinate

Key Product Details

Product Description

Vatalanib succinate is a potent VEGFR inhibitor (IC₅₀ values are 37 and 77 nM for VEGFR-2 and -1, respectively). Inhibits proliferation, migration and survival of HUVECs in vitro and inhibits growth, vascularization and metastasis of tumors expressing VEGFR in mouse models. Also inhibits PDGFR-β, c-Kit and c-Fms. Potent aromatase inhibitor (IC₅₀ = 50 nM). Orally available.

Product Specifications for Vatalanib succinate

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Vatalanib succinate

The following data is based on the product molecular weight 464.90.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.15 mL	10.76 mL	21.51 mL
5 mM	0.43 mL	2.15 mL	4.30 mL
10 mM	0.22 mL	1.08 mL	2.15 mL
50 mM	0.04 mL	0.22 mL	0.43 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 5 publications citing the usage of this product.

• Wood PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000 PMID: 10786682
• Bold New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J.Med.Chem. 2000 PMID: 10956229
• Banerjee The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. Cancer Res. 2009 PMID: 19435899

Product Documents for Vatalanib succinate